1. Pink Sheet
  2. >>Advanced Technologies
  3. >>Cell & Gene Therapies

CAR-T Cell Product Development Guidance Covers Previous Recipients, ‘Bridging Therapy’

 
• By Sue Sutter

Testing of autologous therapy in clinical trial patients who previously received CAR-T cells requires special consideration in initial material testing and study design, US FDA says in a draft guidance that also addresses potential need for bridging therapy in the event of a manufacturing delay or failure.

Bridge
Sponsors may need to consider 'bridging therapy' in their CAR-T study protocols. • Source: Alamy

A new US Food and Drug Administration guidance addresses unique challenges in chimeric antigen receptor T-cell product development, including when clinical trial subjects previously have received CAR-T cells and when “bridging therapy” may be needed in the event of a manufacturing delay or failure.

The draft guidance discusses clinical considerations for early-phase development specific to CAR-T products for cancer patients, with particular attention...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cell & Gene Therapies

More from Advanced Technologies

US FDA’s Elsa AI Platform Is Not Guiding Regulatory Decisions, Official Says

 
• By Cathy Kelly

Tala Fakhouri said the agency’s use of the AI tool in the review process has generated lots of questions.

Branch Chief Vijay Kumar Named Acting Head Of US FDA’s Cell, Gene Therapy Office

 
• By Derrick Gingery

Kumar takes over as acting director of the Center for Biologics Evaluation and Research’s Office of Therapeutic Products days after director Nicole Verdun was ousted.

EMA Nod For First MASH Drug Rezdiffra, Cell Therapy Zemcelpro And 11 Others

 
• By Eliza Slawther

Madrigal Pharmaceuticals’ Rezdiffra is on track to become the first medicine approved in the EU for non-cirrhotic metabolic dysfunction-associated steatohepatitis after the European Medicines Agency recommended that it be granted conditional marketing authorization.